Perrigo Company PLC (PRGO)

41.68
-0.19(-0.45%)
  • Volume:
    264,219
  • Day's Range:
    41.48 - 42.02
  • 52 wk Range:
    31.32 - 50.90

PRGO Overview

Prev. Close
41.87
Day's Range
41.48-42.02
Revenue
4.34B
Open
41.82
52 wk Range
31.32-50.9
EPS
-0.872
Volume
264,219
Market Cap
5.6B
Dividend (Yield)
1.04
(2.48%)
Average Vol. (3m)
1,373,462
P/E Ratio
-63.78
Beta
0.907
1-Year Change
2.25%
Shares Outstanding
134,551,671
Next Earnings Date
Nov 09, 2022
What is your sentiment on Perrigo?
or
Vote to see community's results!

Perrigo Company PLC News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Perrigo Company PLC Analysis

Perrigo Company PLC Company Profile

Perrigo Company PLC Company Profile

Employees
9900

Perrigo Company plc is a provider of over the counter (OTC) health and wellness solutions that enables consumers to prevent or treat conditions that can be self-managed. The Company operates through two segments: Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI). The CSCA segment comprises consumer self-care business (OTC, infant formula, and oral self-care categories, and contract manufacturing) in the United States (U.S) and Canada. CSCA segment products sold under brands, such as Prevacid 24HR, Good Sense, Zephrex D, ScarAway, Plackers, Rembrandt, Steripod, Firefly, REACH, Dr. Fresh, and Burt's Bees. The CSCI segment comprises consumer self-care business primarily branded in Europe and Australia, store brand business in the United Kingdom and parts of Europe and Asia. The CSCI segment primarily focuses on building local and regional brands sold through merchandisers, drug stores, pharmacies, and e-commerce channels.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyNeutralSellNeutralSell
Technical IndicatorsBuyStrong SellBuyBuySell
SummaryBuySellNeutralNeutralSell
  • This should be a moderate BUY
    0
    • 42.5. buy
      1
      • sell
        1
        • md ayas
          0
          • February 27 Earnings call was terribly executed. The CEO was full of excuses as to why he is clueless on the future of the company. They missed earnings and could not give clear answers as the reasons. They demanded for their investors to wait until May 6 for guidance, as they do not know what they are going to do with the business. They only thing they would say is the product pricing is a headwind that will not end, they want to divest the Rx business but there are no buyers, and that they will continue to fight the tax dispute but can not make any claims about its possible outcome.
            0
            • he is just doing that he was joking around
              0
          • I'll be glad if it goes up to $85. Let's hope it will exceed analysts' expectations and maybe beat by a few cents. Cross your fingers pal!
            1
            • prgo had good Q1 2016 earning why she isnt at 130$ yet?
              0